期刊文献+

多发性骨髓瘤患者并发症的观察与护理 被引量:3

Observation and Nursing of Complications in Patients with Multiple Myeloma
下载PDF
导出
摘要 目的整理该院多发性骨髓瘤患者的并发症发病资料,探讨护理干预对多发性骨髓瘤患者的并发症护理效果。方法整群选取该院2015年1—12月收治的86例多发性骨髓瘤患者,将其随机分为优质组和常规组,每组各43例患者,优质组采用优质护理,常规组采用常规护理,比较两组护理满意度、并发症发病情况。结果优质组并发症发病率6.97%,常规组并发症发病率27.90%,两组患者的并发症发病率差异有统计学意义(P<0.05),优质组满意度100%,常规组满意度90.69%,差异有统计学意义(P<0.05)。结论多发性骨髓瘤在治疗过程中的并发症较多,发病率高,对患者治疗影响巨大,通过优质护理方法能够有效降低患者并发症的发病率,值得临床推广借鉴。 Objective To study the incidence of complications in patients with multiple myeloma in our hospital,and to explore the effect of nursing intervention on the complications of multiple myeloma patients.Methods Group selection in 2015 January to December of 86 cases of multiple myeloma patients were randomly divided into quality group and routine group,each 43 cases in each group,the group of high-quality with high quality nursing and conventional group used routine nursing care,nursing satisfaction was compared between the two groups,complications of the disease.Results The group of high-quality morbidity 6.97%,conventional group the incidence of complications 27.90%,two groups of patients with complications rate had significant difference was statistically significant(P〈0.05),100% quality satisfaction,conventional group satisfaction 90.69%,significant difference with statistical significance(P〈0.05).Conclusion Multiple myeloma in the treatment of complications,the incidence rate is high,and will have a huge impact in the treatment of patients with,by high quality nursing method can effectively reduce the incidence of complications of patients,is worthy of clinical reference.
作者 蔡瑞娜
出处 《中外医疗》 2016年第24期154-156,共3页 China & Foreign Medical Treatment
关键词 多发性骨髓瘤 优质护理 常规护理 并发症发病率 比较分析 Multiple myeloma Quality care Routine nursing Incidence of complications Comparative analysis
  • 相关文献

参考文献5

二级参考文献30

  • 1邓宏,龙顺钦,吴万垠,薛晓光,孙良生,柴小姝,河文峰.艾灸防治化疗致白细胞减少症46例疗效观察[J].新中医,2007,39(6):90-91. 被引量:37
  • 2刘琨,李达,张宏业.87例多发性骨髓瘤的中医证型分析[J].新中医,2007,39(8):57-58. 被引量:15
  • 3尤黎明.内科护理学[M].北京:人民卫生出版社,2005:222.
  • 4Bross PF,KaneR,Farrell AT,et al. Approval summary for borte- zomib for injection in the treatment of multiple myeloma [Jl. Clin Cancer Res,2004,10:3954-3964.
  • 5Moreau P,Pylypenko H. Subcutaneous versus intravenous ad- ministration of bortezomib in patients with relapsed multiple myeloma:a randomized,phase 3,non-inferiority study[J]. Lancet, 2011,12:433-437.
  • 6The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies,multiple myeloma and related disorders:a report of the International Myeloma Working Group [ J ]. British Journal of Haematology, 2003,121 (5) :749-757.
  • 7Tortti A,Colevas AD,Setser A,et al. Development of a com- prehensive grading system for the adverse effects of cancer treatment[J].Semin Radiat Oncol,2003,13(3) : 176-181.
  • 8Berkowitz A,Walker S. Bortezomib-induced peripheral neuropa- thy in patients with multiple myeloma[J]. Clin J Oncol Nurs, 2012,16( 1 ) :86-89.
  • 9Oakervee HE,Popat R,Curry N,et al. PAD combination thera- py(PS-341/bortezomib,doxorubicin and dexamethesone) for pre- viously untreat patients with multiple myeloma[J]. Br J Haema- tol,2005,129(6) :755-762.
  • 10薛艳红.多发性骨髓瘤的个体化护理体会[J].中外健康文摘,2012,9(19):316-317.

共引文献48

同被引文献35

引证文献3

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部